Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

OMER

Omeros Corporation

Last Close
May 10 • 04:00PM ET
3.51
Dollar change
-0.05
Percentage change
-1.40 		%
Held by: VTI IWM VXF IWN SCHA VTWO IWO FDM IWC SMLF
IndexRUT P/E- EPS (ttm)-1.88 Insider Own4.05% Shs Outstand61.13M Perf Week-5.90%
Market Cap203.37M Forward P/E- EPS next Y-1.79 Insider Trans1.08% Shs Float55.60M Perf Month-10.91%
Income-117.81M PEG- EPS next Q-0.56 Inst Own43.10% Short Float24.41% Perf Quarter-8.12%
Sales0.00M P/S- EPS this Y-11.17% Inst Trans-13.89% Short Ratio31.05 Perf Half Y170.00%
Book/sh-0.41 P/B- EPS next Y14.21% ROA-36.09% Short Interest13.57M Perf Year-42.08%
Cash/sh2.97 P/C1.18 EPS next 5Y- ROE-576.33% 52W Range0.92 - 7.80 Perf YTD7.34%
Dividend Est.- P/FCF2.74 EPS past 5Y6.37% ROI-36.49% 52W High-54.99% Beta1.37
Dividend TTM- Quick Ratio4.09 Sales past 5Y34.87% Gross Margin- 52W Low281.52% ATR (14)0.24
Dividend Ex-Date- Current Ratio4.09 EPS Y/Y TTM-348.50% Oper. Margin0.00% RSI (14)52.00 Volatility6.43% 6.81%
Employees198 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin- Recom2.00 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-107.08% Payout- Rel Volume0.45 Prev Close3.56
Sales Surprise- EPS Surprise72.97% Sales Q/Q- EarningsApr 01 AMC Avg Volume437.07K Price3.51
SMA204.59% SMA50-2.53% SMA20011.14% Trades Volume198,183 Change-1.40%
Date Action Analyst Rating Change Price Target Change
Dec-08-22Downgrade UBS Buy → Neutral $12 → $2
Nov-08-22Downgrade BofA Securities Neutral → Underperform $8 → $3
Jun-08-22Downgrade BofA Securities Buy → Neutral $12 → $4
Oct-08-21Downgrade JP Morgan Neutral → Underweight
Oct-01-21Downgrade Wedbush Neutral → Underperform
Oct-01-21Downgrade Maxim Group Buy → Hold
Sep-27-21Initiated JP Morgan Neutral $15
Feb-01-21Initiated UBS Buy $25
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
Show Previous Ratings
May-10-24 08:50AM
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
(Business Wire)
May-09-24 08:50AM
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
(Business Wire)
Apr-02-24 12:41PM
Q4 2023 Omeros Corp Earnings Call
(Thomson Reuters StreetEvents)
11:22AM
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Apr-01-24 09:53PM
OMER Stock Earnings: Omeros Misses EPS for Q4 2023
(InvestorPlace) -7.54%
05:32PM Loading…
05:32PM
Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results
(GuruFocus.com)
04:17PM
Omeros: Q4 Earnings Snapshot
(Associated Press Finance)
04:02PM
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
(Business Wire)
Mar-27-24 08:30AM
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
(Business Wire)
Mar-17-24 10:02AM
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade
(InvestorPlace)
Feb-20-24 09:00AM
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
(Business Wire)
Feb-07-24 09:34AM
3 Sleeper Stocks Under $15 Ready to Explode by 2029
(InvestorPlace)
Feb-01-24 09:11AM
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
(Business Wire)
Dec-24-23 01:08PM
7 Short-Squeeze Stocks That Are Screaming for Speculation
(InvestorPlace)
Nov-11-23 03:01PM
Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript
(Insider Monkey)
09:43AM Loading…
Nov-10-23 09:43AM
Q3 2023 Omeros Corp Earnings Call
(Thomson Reuters StreetEvents)
Nov-09-23 04:33PM
Omeros: Q3 Earnings Snapshot
(Associated Press Finance)
04:02PM
Omeros Corporation Reports Third Quarter 2023 Financial Results
(Business Wire)
Nov-06-23 08:00AM
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
(Business Wire) +6.25%
Nov-03-23 09:05AM
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
(Business Wire)
Nov-02-23 09:05AM
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
(Business Wire) +7.96%
Oct-19-23 08:30AM
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
(Business Wire) -10.32%
Oct-16-23 08:36AM
Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price
(FierceBiotech.com) -32.16%
07:59AM
UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage study
(Reuters)
07:44AM
Omeros to shut kidney disease trial as therapy fails in late-stage study
(Reuters)
07:30AM
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
(Business Wire)
Aug-09-23 08:08AM
Omeros: Q2 Earnings Snapshot
(Associated Press Finance)
08:00AM
Omeros Corporation Reports Second Quarter 2023 Financial Results
(Business Wire)
Aug-04-23 08:00AM
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
(Business Wire)
Jun-21-23 08:30AM
Omeros Announces Webcast Details for Annual Meeting of Shareholders
(Business Wire) -7.31%
02:47PM Loading…
Jun-12-23 02:47PM
Why Shares of Omeros Dropped on Monday
(Motley Fool) -14.53%
08:45AM
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
(Business Wire)
Jun-01-23 11:00AM
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
(Business Wire) +17.42%
May-09-23 04:41PM
Omeros: Q1 Earnings Snapshot
(AP Finance)
04:02PM
Omeros Corporation Reports First Quarter 2023 Financial Results
(Business Wire)
May-04-23 04:06PM
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
(Business Wire)
Apr-25-23 09:25AM
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
(Business Wire) -5.32%
Apr-10-23 08:45AM
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
(Business Wire) +7.31%
Mar-29-23 09:07AM
Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day
(Zacks) +9.42%
Mar-28-23 09:34AM
3 Medical Stocks Creating Wealth Despite Macro Challenges
(Zacks)
Mar-14-23 11:11AM
Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript
(Insider Monkey) +9.28%
10:06AM
Q4 2022 Omeros Corp Earnings Call
(Thomson Reuters StreetEvents)
Mar-13-23 04:02PM
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
(Business Wire) +5.83%
Mar-10-23 03:37PM
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
(Business Wire) -10.93%
Mar-07-23 09:00AM
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
(Business Wire)
Feb-09-23 02:43PM
Why Omeros Stock Bolted Higher This Week
(Motley Fool)
Feb-06-23 11:30AM
Why Omeros Corporation Stock Is Skyrocketing Today
(Motley Fool) +61.17%
08:50AM
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
(Business Wire)
Nov-09-22 04:02PM
Omeros Corporation Reports Third Quarter 2022 Financial Results
(Business Wire) -11.88%
Nov-08-22 08:30AM
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
(Business Wire)
Nov-04-22 09:00AM
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
(Business Wire) -5.03%
Nov-03-22 09:00AM
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
(Business Wire)
Oct-03-22 07:10AM
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
(Business Wire) +10.79%
Sep-15-22 10:51AM
Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless
(Benzinga) -25.97%
09:06AM
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
(Business Wire)
09:02AM
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
(Business Wire)
Aug-17-22 08:40AM
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
(Business Wire)
Aug-10-22 05:01PM
Omeros reports growing Omidria sales after deal with British eye care company
(American City Business Journals) +20.32%
Aug-09-22 04:02PM
Omeros Corporation Reports Second Quarter 2022 Financial Results
(Business Wire) -8.15%
Aug-08-22 11:35AM
How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own?
(Simply Wall St.)
Aug-04-22 09:55AM
Wall Street Analysts See a 126% Upside in Omeros (OMER): Can the Stock Really Move This High?
(Zacks) +6.51%
08:30AM
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
(Business Wire)
Jul-29-22 02:48PM
Why Omeros Corporation Stock Is Marching Higher Today
(Motley Fool) +11.41%
08:45AM
FDA Grants Orphan Drug Designation to Omeros MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
(Business Wire)
Jul-05-22 05:46PM
Why Omeros Stock Is Freefalling Today
(Motley Fool) -33.41%
Jun-15-22 08:00AM
Omeros Announces Webcast Details for Annual Meeting of Shareholders
(Business Wire) +5.13%
May-10-22 04:02PM
Omeros Corporation Reports First Quarter 2022 Financial Results
(Business Wire)
May-04-22 08:30AM
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
(Business Wire) +6.06%
Apr-20-22 08:45AM
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
(Business Wire) -8.30%
Mar-01-22 04:02PM
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
(Business Wire)
08:59AM
How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own?
(Simply Wall St.)
Feb-28-22 08:34AM
Why Earnings Season Could Be Great for Omeros (OMER)
(Zacks)
Feb-24-22 07:00AM
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
(Business Wire) +7.74%
Feb-03-22 09:38AM
Bellevue Asset Management, Llc Buys First Trust Low Duration Mortgage Opportunities ET, eBay ...
(GuruFocus.com)
Jan-20-22 06:54AM
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
(Benzinga)
Jan-19-22 05:52PM
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
(Business Wire)
Dec-30-21 05:11PM
Omeros receives $126M in sale of drug franchise to British eye care company
(American City Business Journals)
Dec-23-21 09:10AM
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
(Business Wire)
Dec-20-21 09:30AM
OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER
(PR Newswire) +5.59%
Dec-15-21 11:34AM
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
(Zacks)
Dec-03-21 08:17PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
(Newsfile) -6.15%
Dec-02-21 08:22PM
Seattle biotech Omeros selling drug franchise in deal valued at over $1B
(American City Business Journals) +7.33%
07:30AM
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
(Business Wire)
05:58AM
Omeros Shares Rally On Agreement to Sell Omidria Cataract Business
(Investing.com)
Nov-30-21 07:42AM
Investors in Omeros (NASDAQ:OMER) have unfortunately lost 50% over the last three years
(Simply Wall St.)
Nov-09-21 06:25PM
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
04:02PM
Omeros Corporation Reports Third Quarter 2021 Financial Results
(Business Wire)
Nov-05-21 04:45PM
Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years
(Benzinga)
08:40AM
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
(Business Wire)
08:30AM
Omeros Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
(Business Wire)
Nov-04-21 10:53AM
Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?
(Zacks)
08:30AM
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
(Business Wire)
Nov-01-21 04:35PM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
(ACCESSWIRE) +9.73%
03:01PM
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Oct-31-21 06:19AM
3 Beaten-Down Biotech Stocks -- Can They Recover?
(Motley Fool)
Oct-26-21 03:15PM
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
(ACCESSWIRE)
Oct-21-21 10:00AM
Down 59.6% in 4 Weeks, Here's Why Omeros (OMER) Looks Ripe for a Turnaround
(Zacks)
Oct-20-21 08:31AM
Omeros (OMER) Soars 9.7%: Is Further Upside Left in the Stock?
(Zacks)
Oct-18-21 05:39PM
Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA
(Benzinga) -26.65%
12:24PM
Here's Why Omeros Is Sinking Further Today
(Motley Fool)
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Demopulos Gregory A MDChairman, CEO & PresidentNov 17 '23Buy1.6815,00025,200123,945Nov 21 08:11 PM
Demopulos Peter A MDDirectorNov 15 '23Buy1.5310,00015,300208,516Nov 17 09:46 PM
Cable Thomas J.DirectorMay 22 '23Option Exercise5.305,00026,50040,067May 23 05:50 PM
HANISH ARNOLD CDirectorMay 22 '23Option Exercise5.305,00026,5005,000May 23 05:53 PM
Cable Thomas J.DirectorMay 22 '23Sale6.535,00032,65035,067May 23 05:50 PM
HANISH ARNOLD CDirectorMay 22 '23Sale6.465,00032,3000May 23 05:53 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

SLRX

Salarius Pharmaceuticals Inc

Last Close
May 10 • 04:00PM ET
0.5000
Dollar change
-0.0074
Percentage change
-1.46 		%
SLRX Salarius Pharmaceuticals Inc daily Stock Chart
Held by: MEDX VXF
Index- P/E- EPS (ttm)-4.54 Insider Own6.73% Shs Outstand4.78M Perf Week-0.20%
Market Cap2.39M Forward P/E- EPS next Y-23.50 Insider Trans0.00% Shs Float4.45M Perf Month2.04%
Income-12.54M PEG- EPS next Q-6.70 Inst Own4.86% Short Float1.65% Perf Quarter-12.13%
Sales0.00M P/S- EPS this Y-597.92% Inst Trans-3.23% Short Ratio0.62 Perf Half Y-33.33%
Book/sh1.34 P/B0.37 EPS next Y12.31% ROA-118.12% Short Interest0.07M Perf Year-66.22%
Cash/sh1.23 P/C0.41 EPS next 5Y- ROE-160.07% 52W Range0.43 - 1.87 Perf YTD-23.08%
Dividend Est.- P/FCF- EPS past 5Y64.97% ROI-237.22% 52W High-73.25% Beta1.04
Dividend TTM- Quick Ratio5.02 Sales past 5Y-7.25% Gross Margin- 52W Low16.28% ATR (14)0.05
Dividend Ex-Date- Current Ratio5.02 EPS Y/Y TTM40.18% Oper. Margin0.00% RSI (14)48.16 Volatility7.73% 8.23%
Employees2 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price3.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q92.08% Payout- Rel Volume0.04 Prev Close0.51
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 22 AMC Avg Volume118.87K Price0.50
SMA200.01% SMA50-8.49% SMA200-24.82% Trades Volume4,244 Change-1.46%
Date Action Analyst Rating Change Price Target Change
Apr-27-20Initiated Ladenburg Thalmann Buy $3.80
Mar-22-24 09:52PM
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023
(InvestorPlace) +5.96%
04:34PM
Salarius: Q4 Earnings Snapshot
(Associated Press Finance)
04:05PM
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
Feb-22-24 08:00AM
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
(GlobeNewswire)
Jan-16-24 08:00AM
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
(GlobeNewswire)
08:30AM Loading…
Jan-03-24 08:30AM
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
(GlobeNewswire)
Nov-10-23 05:03AM
Salarius: Q3 Earnings Snapshot
(Associated Press Finance)
Nov-07-23 08:30AM
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
(GlobeNewswire)
Aug-10-23 05:10PM
Salarius: Q2 Earnings Snapshot
(Associated Press Finance) -9.32%
04:05PM
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Aug-09-23 07:39AM
SLRX Pursuing Strategic Alternatives
(Zacks) -9.96%
Aug-08-23 04:05PM
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
(GlobeNewswire)
Jul-11-23 09:00AM
SLRX Continues Cancer Fight with Phase I Trial Approval
(Zacks) -12.41%
08:30AM
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
(GlobeNewswire)
Jun-12-23 08:00AM
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
(GlobeNewswire)
04:05PM Loading…
May-16-23 04:05PM
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
May-12-23 08:00AM
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
May-11-23 08:20AM
Salarius: Q1 Earnings Snapshot
(AP Finance) -5.41%
08:00AM
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
May-09-23 08:00AM
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
(GlobeNewswire) -16.20%
07:34AM
SLRX: Fighting Cancer Through Two Paths
(Zacks Small Cap Research)
May-01-23 08:30AM
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164
(GlobeNewswire)
Apr-20-23 08:30AM
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
(GlobeNewswire) -10.75%
Apr-04-23 04:02PM
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
(GlobeNewswire) -12.32%
12:00PM
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023
(GlobeNewswire)
Mar-27-23 08:30AM
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-15-23 11:00AM
Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting
(GlobeNewswire)
Mar-07-23 08:00AM
Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia
(GlobeNewswire)
Feb-16-23 08:30AM
Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas
(GlobeNewswire)
Jan-27-23 08:30AM
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
(GlobeNewswire) -5.47%
08:30AM Loading…
Jan-19-23 08:30AM
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
(GlobeNewswire) +52.99%
Jan-05-23 08:00AM
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
(GlobeNewswire)
Dec-13-22 08:01AM
Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting
(GlobeNewswire) -5.32%
08:00AM
Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting
(GlobeNewswire)
Dec-08-22 08:00AM
Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH
(GlobeNewswire)
Dec-01-22 08:00AM
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire) -5.18%
Nov-10-22 08:30AM
Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Nov-03-22 09:57AM
Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
(GlobeNewswire)
Oct-27-22 08:30AM
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
(GlobeNewswire) -14.40%
Oct-19-22 08:30AM
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
(GlobeNewswire) -15.73%
Oct-18-22 08:30AM
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire) -45.18%
Oct-14-22 08:43AM
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
(GlobeNewswire) -13.81%
Sep-20-22 12:00PM
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
(GlobeNewswire)
Sep-13-22 08:00AM
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
(GlobeNewswire) +10.10%
Aug-22-22 08:30AM
Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire) -9.29%
Aug-08-22 08:30AM
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) +9.95%
Aug-04-22 08:30AM
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire)
Aug-02-22 08:30AM
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
(GlobeNewswire) -6.07%
Jul-29-22 09:15AM
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
(GlobeNewswire)
Jun-09-22 07:33AM
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
(GlobeNewswire)
May-18-22 04:10PM
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
(GlobeNewswire) +20.62%
May-12-22 04:05PM
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
(GlobeNewswire) +38.75%
May-11-22 04:05PM
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
(GlobeNewswire) -16.93%
May-05-22 07:30AM
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
(GlobeNewswire)
Apr-22-22 08:30AM
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
(GlobeNewswire) -20.54%
Mar-10-22 04:05PM
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
(GlobeNewswire) +33.40%
Mar-03-22 07:31AM
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
(GlobeNewswire)
Feb-17-22 08:01AM
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
(GlobeNewswire)
Feb-15-22 09:00AM
Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022
(GlobeNewswire)
Feb-08-22 08:00AM
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
(GlobeNewswire)
Feb-03-22 07:30AM
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
(GlobeNewswire)
Jan-14-22 01:52PM
Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition
(American City Business Journals)
Jan-13-22 07:00AM
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
(GlobeNewswire)
Jan-06-22 12:45PM
Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"
(GlobeNewswire) -6.06%
Dec-29-21 08:03AM
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
(GlobeNewswire) -6.19%
Dec-20-21 08:35AM
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
(PR Newswire)
Dec-15-21 08:31AM
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
(GlobeNewswire)
Dec-14-21 08:35AM
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
(PR Newswire)
Nov-29-21 08:01AM
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
(GlobeNewswire)
Nov-04-21 04:05PM
Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
Oct-28-21 03:06PM
Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Oct-26-21 08:01AM
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
(GlobeNewswire)
Oct-07-21 09:05AM
Salarius Pharmaceuticals and Nationwide Childrens Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Oct-05-21 08:01AM
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
(GlobeNewswire)
Sep-30-21 04:35PM
Salarius Pharmaceuticals and Nationwide Childrens Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-28-21 07:01AM
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
(GlobeNewswire)
Sep-27-21 08:03AM
Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference
(GlobeNewswire) -5.22%
Sep-22-21 07:33AM
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
(GlobeNewswire)
Sep-20-21 08:35AM
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
(GlobeNewswire)
07:33AM
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
(GlobeNewswire)
Sep-15-21 08:03AM
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
(GlobeNewswire)
Sep-10-21 08:35AM
Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th
(GlobeNewswire)
Sep-08-21 08:13AM
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
(GlobeNewswire)
Aug-12-21 02:00PM
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
(GlobeNewswire)
09:00AM
Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference
(GlobeNewswire)
Aug-10-21 06:16AM
Here's Why We're Not Too Worried About Salarius Pharmaceuticals' (NASDAQ:SLRX) Cash Burn Situation
(Simply Wall St.)
Aug-05-21 07:32AM
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
Jul-29-21 07:33AM
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
(GlobeNewswire)
Jul-14-21 08:05AM
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit
(GlobeNewswire)
Jul-13-21 07:33AM
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire)
Jul-09-21 07:33AM
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
(GlobeNewswire) +7.92%
Jun-17-21 08:03AM
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
(GlobeNewswire)
Jun-15-21 07:30AM
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
(GlobeNewswire)
Jun-10-21 01:30PM
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
(GlobeNewswire)
Jun-07-21 07:35AM
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstats Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
(GlobeNewswire)
May-19-21 05:01PM
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
(GlobeNewswire) -6.21%
May-12-21 04:05PM
Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights
(GlobeNewswire)
02:45PM
Salarius Pharmaceuticals Inc to Host Earnings Call
(ACCESSWIRE)
May-05-21 07:05AM
Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results
(GlobeNewswire)
Apr-29-21 07:30AM
Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting
(GlobeNewswire)
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.